Rheumnow Podcast

Dive into the highlights from the ACR 2024 meeting in Washington, DC, featuring exciting advancements in rheumatology treatments. Discover innovative therapies for conditions like rheumatoid arthritis and lupus, as well as the environmental impact of adalimumab and its biosimilars. Learn about the promising effects of GLP-1 drugs and groundbreaking AI-driven ultrasound technology in diagnostics. The discussion wraps up with upcoming events for networking and collaboration in the field. Tune in for a mix of insights and practical updates!

In this engaging discussion, Lihi Eder, an expert in psoriatic arthritis from the University of Toronto, Sheila Reyes, a Filipino rheumatologist, and Adela Castro, a clinical assistant professor in Memphis, tackle the latest breakthroughs in spondyloarthritis. They dive into challenges in diagnosing axial spondyloarthritis and the importance of updated classification criteria. Gender differences in treatment responses and personalized approaches are highlighted, along with insights on treatment failures and strategic switches between biologic therapies. Tune in for essential insights!

A New ACR Cancer Survival in RA "Changing Mindsets about Methotrexate Side Effects" Control RA, Build Stronger Bones Cumulative Steroid Use and Cardiovascular Events Disease Activity in RA-ILD Do TNFis and JAKis Prevent Cancer!? Estimating Inflammation, Damage and Patient Distress Finding the Right Combination Therapy in RA Implantable Vagus Nerve Stimulator for RA Is Frequent Lab Monitoring Necessary? Long Term Follow up from APIPPRA Metabolic Dysregulation and RA Interstitial Lung Disease Native Americans with RA Die Young Paraoxonase-1: Possible Biomarker for Progression to RA Pred Softly: Steroids Predicting Flares in Rheumatoid Arthritis RA Roundup: Is LDA Inappropriate? What about Statins for JAKs? RA Treatment Adherence: Is decision making really shared? RA: One JAK to Rule Them All? Sonelokimab in PsA: Phase 2 Data Treat-to-Target Improves Fertility in Women with RA Treatment Considerations for RA-ILD Treatment Strategies in RA Use of AI in Hand Ultrasound Scoring Vaccine Responses:The DMARD Counts What's New in Relapsing Polychondritis? What's The State of Biosimilars?

In this engaging discussion, Philip Meese, a seasoned rheumatologist, delves into the latest advancements in IL-17 treatments for psoriatic arthritis and axial spondyloarthritis. He shares intriguing real-world data on the efficacy and safety of Bimekizumab, highlighting significant improvements in pain and fatigue. The conversation also explores treatment strategies comparing TNF and IL-17 inhibitors, revealing insights from a large patient study. Additionally, Meese discusses the long-term safety profile of Bimekizumab and other emerging therapies, emphasizing personalized patient care.

Richard Conway, a vasculitis specialist, discusses pivotal findings from ACR 2024. Peter Nash delves into the role of JAK inhibitors, while Janet Pope reviews treatment strategies for polymyalgia rheumatica and giant cell arteritis. Eric Dian analyzes intriguing oral abstracts on rheumatoid arthritis, and David Liu emphasizes cardiovascular risks associated with treatments. They explore the safety of JAKs, advances in managing RA during COVID-19, and the efficacy of new therapies for PMR and GCA, showcasing innovative strategies for improving patient outcomes.

Andrea Fava is an expert in lupus nephritis diagnostics, while Chris Winkup is a consultant rheumatologist focused on CAR-T therapy. They dive into the challenges of diagnosing lupus nephritis with new non-invasive biomarkers. The discussion highlights the impact of positive ANA patterns on liver disease, and the advancements in CAR-T therapy for targeting harmful B-cells. They also touch upon vaccination responses and the complexities surrounding neuropsychiatric lupus, emphasizing the need for enhanced patient-clinician communication.

Adela Castro presents CLASSIC study results, exploring the ASAS criteria for axSpA. Anthony Chan discusses the BASTI score and defines difficult-to-manage axSpA. Marina Magre highlights key abstracts from the ACR meeting. Dr. Sheila Reyes explains how machine learning predicts flares and the impact of gender on axSpA. Professor Walter Maximowicz shares the 3-4-5 rule for interpreting positive MRI findings, enhancing understanding of spondyloarthritis diagnostics. Together, they showcase significant advancements in research and treatment strategies.

Catherine Bakewell, a seasoned rheumatologist and ultrasound expert, Philip Meese, a dedicated researcher on bimekizumab, and Artie Kavanaugh, an insightful rheumatologist reporting on ACR updates, dive into cutting-edge topics. They discuss the promising results of bimekizumab in alleviating pain and fatigue in psoriatic arthritis. Insights into the implications of weight loss drugs on treatment outcomes are explored, alongside crucial findings on sex differences affecting disease impact, driving home the need for tailored strategies in patient care.

Join Dr. David Liew, a renowned rheumatologist, as he dives into the role of JAK inhibitors in treating polymyalgia rheumatica. He discusses the recent breakthroughs that are reshaping treatment strategies and making these therapies more accessible. The conversation also turns to the cardiovascular risks associated with JAK inhibitors, compared to traditional steroid use. Liew's insights highlight the importance of evaluating both benefits and risks in personalized rheumatology care.

Dr. Guillermo Valenzuela, a leading expert in rheumatology, shares groundbreaking insights on apremilast's efficacy for psoriatic arthritis from the Mosaic Trial. He also discusses an innovative approach to rheumatoid arthritis treatment using an implantable vagus nerve stimulator, showcasing its potential for patients who haven’t responded to standard therapies. The conversation highlights advancements in managing these conditions and the promising implications for patient care.